In current clinical practice in Japan, measurable biomarkers for colorectal cancer treatment include RAS gene mutations (up to 50% of cases), BRAF gene mutations (up to 7%), mismatch repair deficiency (MSI-H/dMMR: ~ 15%), and HER2 gene amplification (up to 5%). Here, ERBB2 is linked to colorectal cancer.